Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 89.33 percent increase over losses of $(4.50) per share from the same period last year.